Towards DFO*¹²-Preliminary Results of a New Chelator for the Complexation of Actinium-225.

ABSTRACT: Background: Actinium-225 (²²⁵Ac) has gained interest in nuclear medicine for use in targeted alpha therapy (TAT) for the treatment of cancer. However, the number of suitable chelators for the stable complexation of ²²⁵Ac³⁺ is limited. The promising physical properties of ²²⁵Ac result in an increased demand for the radioisotope that is not matched by its current supply. To expand the possibilities for the development of ²²⁵Ac-based TAT therapeutics, a new hydroxamate-based chelator, DFO*¹², is described. We report the DFT-guided design of dodecadentate DFO*¹² and an efficient and convenient automated solid-phase synthesis for its preparation. To address the limited availability of ²²⁵Ac, a small-s

SUBMITTER: Feiner IVJ 

PROVIDER: S-EPMC11946154 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature